Pasar al contenido principal

CANCER GENOMICS

RYC-2013-14554

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Altered oncomodules underlie chromatin regulatory factors driver mutations.

  • Frigola, Joan
  • Iturbide Martínez de Albéniz, Ane, 1989-
  • López Bigas, Núria
  • Peiró Sales, Sandra
  • González-Pérez, Abel
Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs., AGP is supported by a Ramon y Cajal grant (RYC-2013-14554), funded by the Spanish Ministry of Economy,/nwhich also supports the publication of this article.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

  • Genescà, Eulàlia
  • Lazarenkov, A.
  • Morgades, Mireia
  • Berbis, G.
  • Ruiz-Xivillé, Neus
  • Gómez-Marzo, P.
  • Ribera, Jordi
  • Juncà, Jordi
  • González-Pérez, A.
  • Mercadal, Santiago
  • Guàrdia, Ramón
  • Artola, María Teresa
  • Moreno, María José
  • Martínez-López, Joaquín
  • Zamora, Lurdes
  • Barba, Pere
  • Gil, Cristina
  • Tormo, Mar
  • Cladera, Antonia
  • Novo, Andrés
  • Pratcorona, Marta
  • Nomdedéu, Josep F.
  • González-Campos, José A.
  • Almeida, María
  • Cervera, José
  • Montesinos, Pau
  • Batlle, M.
  • Vives, Susana
  • Esteve, Jordi
  • Solé, Francesc
  • Orfao, Alberto
  • Ribera, Josep-Maria
© The Author(s)., Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation., This project was supported by the Asociación Española Contra el Cáncer, AECC (project ref.: GC16173697BIGA), by CERCA Program/Generalitat de Catalunya, the Catalan Government: 2014-SGR225 (GRE), Obra Social “La Caixa” and by Celgene Spain. E. Genescà is the recipient of agrant from the Spanish Health Ministry (ISCIII, CA12/00468) and an unrestricted grant from Gilead.A. Gonzalez-Perez is supported by a Ramon y Cajal fellowship (RYC-2013-14554) of the Educational Ministry (Madrid, Spain). This work was also partially supported by FEDER funds from the ISCIII (PT13/0010/0026, CIBERONC (CB16/12/00284 and CB16/12/00400), Madrid, Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Altered oncomodules underlie chromatin regulatory factors driver mutations.

  • Frigola, Joan
  • Iturbide Martínez de Albéniz, Ane, 1989-
  • López Bigas, Núria
  • Peiró Sales, Sandra
  • González-Pérez, Abel
Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs., AGP is supported by a Ramon y Cajal grant (RYC-2013-14554), funded by the Spanish Ministry of Economy,/nwhich also supports the publication of this article.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero, David
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Deu-Pons, Jordi
  • Schroeder, Michael P.
  • Vivancos, Ana|||0000-0003-2888-6512
  • Rovira, Ana|||0000-0003-1301-2599
  • Tusquets, Ignasi
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rodón Ahnert, Jordi
  • Tabernero, Josep|||0000-0002-2495-8139
  • De Torres, Carmen
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org. The online version of this article (10.1186/s13073-018-0531-8) contains supplementary material, which is available to authorized users.